Management of low risk and low PSA prostate cancer: Long term results from the prostate cancer intervention versus observation trial

Recent Results in Cancer Research

Volumn 202, Issue , 2014, Pages 149-169

  Wilt, Timothy J ^a  

^a Minneapolis VA Center for Chronic Disease Outcomes Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BONE METASTASIS; CANCER SURVIVAL; ERECTILE DYSFUNCTION; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MULTICENTER STUDY (TOPIC); OBSERVATION; OVERALL SURVIVAL; PEROPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURGICAL INFECTION; TREATMENT OUTCOME; URINARY TRACT INFECTION; URINE INCONTINENCE; AGE DISTRIBUTION; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CHARLSON COMORBIDITY INDEX; CONTROLLED STUDY; GLEASON SCORE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN TISSUE; INTERVENTION STUDY; LIFE EXPECTANCY; LOW RISK PATIENT; MORBIDITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT RESPONSE;

AGED; BONE NEOPLASMS; CAUSE OF DEATH; FOLLOW-UP STUDIES; HUMANS; MALE; MULTICENTER STUDIES AS TOPIC; NEOPLASM GRADING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TIME FACTORS;

EID: 84958529805     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-45195-9_18     Document Type: Article

References (46)

1. Albertsen PC, Hanley JA, Barrows GH et al (2005) Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 97: 1248-1253
2. Andriole G, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church T et al (2012) PLCO project team. Prostate cancer screening in the randomized prostate, lung colorectal, ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 104: 125-132
3. Basch E, Oliver TK, Vickers A, Thompson I, Kantoff P, Parnes H et al (2012) Screening for prostate cancer with prostate-specific antigen testing: American society of clinical oncology provisional clinical opinion. J Clin Oncol 30: 1-6
4. Bill-Axelson A, Holmberg L, Filen F et al (2008) Radical prostatectomy versus watchful waiting in localized prostate cancer: The Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 100: 1144-1154
5. Bill-Axelson A, Holmberg L, Ruutu M et al (2011) Radical prostatectomy versuswatchful waiting in localized prostate cancer: The Scandinavian prostate cancer group-4 randomized trial. N Engl J Med 264: 1708-1717
6. Coen JJ, Feldman AS, Smith MR, Zietman AL (2011) Watchful waiting for localized prostate cancer in the PSA era: what have been the triggers for intervention? 107: 1582-1586.22
7. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR (2007) Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 178(3 pt 2):S14-S19
8. Cooperberg MR, Broering JM, Carroll PR (2010) Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28: 1117-1123
9. D'Amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiationtherapy for clinically localized prostate cancer. JAMA 280: 969-974
10. Daskivich TJ, Fan K-H, Koyama T, Albertsen PC, Goodman M, Hamilton AS et al (2013) Effect of age, Tumor risk, and comorbidity on competing risks for survival in a U.S. population- based cohort of men with prostate cancer. Ann Intern Med 158(10): 709-717
11. Djulbegovic M, Beyth RJ, Neuberger MM, Stoffs TL, Vieweg J, Djulbegovic B, Dahm P (2010) Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 341:c4543
12. Donovan JL, Mills N, Smith, Brindle L, Jacoby A, Peters T et al (2002) Improving design and conduct of randomized trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. BMJ 325: 766-770
13. Dubben H-H (2009) Trials of prostate cancer screening are not worthwhile. Lancet Oncol 10: 294-9823
14. Eastham JA, Kattan MW, Riedel E, Begg CB, Wheeler TM, Gerigk C, Gonen M, Reuter V, Scardino PT (2003) Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol 170: 2292-2295
15. Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE (1993) Prostate patient outcomes research team. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA 269(20): 2650-2658
16. Ganz PA, Barry JM, Burke W, Col NF, Corso PS, Dodson E et al (2012) National institutes of health state-of-the-science conference: role of active surveillance in the management of men with localized prostate cancer. Ann Intern Med 156(8): 591-595
17. Ghani KR, Grigor K, Tulloch DN, Bollina PR, McNeill SA (2005) Trends in reporting gleason score 1991 to 2001: Changes in the pathologist's practice. Eur Urol 47: 196-201
18. Gleason DF (1977) The Veteran's administration cooperative urologic research group: histologic grading and clinical staging of prostatic carcinoma. In: Tannenbaum M (ed) Urologic pathology: the prostate. Lea and Febiger, Philadelphia, pp 171-198
19. Graham J, Baker M, Macbeth F, Titshall V (2008) On behalf of the guideline development group. Diagnosis and treatment of prostate cancer: summary of NICE guidance. BMJ 336: 610-612
20. Gulati R, Gore JL, Etzioni R (2013) Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med 158: 145-153
21. Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, Kantoff PW, Lee P et al (2013) Observation versus Initial treatment for men with localized, low risk protate cancer. A cost-effectiveness analysis. Ann Intern Med 158: 853-880 http://consensus.nih.gov/2011/docs/prostate/ASPC%20Final%20Draft%20Statement. pdf. Accessed 26 Jan 2012
22. Iversen P, Madsen PO, Corle DK (1995) Radical prostatectomy versus expectanttreatment for early carcinoma of the prostate. Twenty-three yearfollow-up of a prospective randomized study. Scan J Urol Nephrol Suppl 172: 65-72
23. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A (2010) Clinical results of long-term follow-up of a large active surveillance cohort with localized prostate cancer. J Clin Oncol 28: 126-131
24. Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS et al (2009) JAMA 302(11): 1202-1209
25. Moyer VA on behalf of the (2012) U.S. preventive services task force. screening for prostate cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 157: 120-134
26. Newschaffer CJ, Otani K, McDonald MK, Penberthy LT (2000) Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J Natl Cancer Inst 92: 613-621
27. Obek C, Sadek S, Lai S, Civantos F, Rubinowicz D, Soloway MS (1999) Positive surgical margins with radical retropubic prostatectomy: anatomic site-specific pathologic analysis and impact on prognosis. Urology 54: 682-688
28. Ohori M, Wheeler TM, Kattan MW, Goto Y, Scardino PT (1995) Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 154: 1818-1824
29. Qaseem A, Barry MJ, Denberg TD, Owens DK, Shekelle P (2013) For the clinical guidelines committee of the american college of physicians. Screening for prostate cancer: A guidance statement from the clinical guidelines committee of the American college of physicians. Ann Intern Med 158: 761-769
30. Rosario DJ, Lane JA, Metcalfe C, Donovan JL, Doble A et al (2012) Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. BMJ 344:d7894
31. Schellhammer P, Cockett A, Boccon-Gibod L et al (1997) Assessment of endpoints for clinical trials for localized prostate cancer. Urology 49: 27-38
32. Schroder F, Hugosson J, Roobol M, Tammela T, Ciatto S, Nelen V et al (2012) Prostate-cancer mortality at 11 years of follow-up in a randomized European study. New Engl J Med 366: 981-990
33. Shao Y-H, Demissie K, Shih W et al (2009) Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst 101: 1280-1283
34. Shteynshlyuger A, Andriole GL (2011) Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the Eruopean study of screening for prostate cancer. J Urol 185: 828-832
35. Stamey TA, Johnstone IM, McNeal JE, Lu AY, Yemoto CM (2002) Preoperative serum prostate specific antigen levels between 2 and 22 ng/mL correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng/mL. J Urol 167: 103-111
36. Swindle P, Eastham JA, Ohori M et al (2005) Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 174: 903-907
37. Thompson IM, Klotz L (2010) Active surveillance for prostate cancer. JAMA 204: 2411-2412
38. Vis AN, Schröder FH, van der Kwast TH (2006) The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer. Eur Urol 50: 258-265
39. Welch HG, Albertsen PC (2009) Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 101: 1325-1329
40. Welch HG, Black WC (2010) Overdiagnosis in cancer. J Natl Cancer Inst 102: 605-613
41. Welch HG, Schwartz LM, Woloshin S (2005) Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. J Natl Cancer Inst 97: 1132-1137
42. Widmark A (2011) Prospective Randomized Trial Comparing External Beam Radiotherapy versus Watchful Waiting in Early Prostate Cancer. Abstract. Annual Meeting of the American Society of Radiation Oncology
43. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL (2008a) Systematicreview: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 148: 435-448
44. Wilt TJ, Shamliyan T, Taylor B, MacDonald R, Tacklind J, Rutks I, Koeneman K, Cho C-S, Kane RL (2008) Comparative effectiveness of therapies for clinically localized prostate cancer. Comparative Effectiveness Review No 13. (Prepared by Minnesota Evidence-based Practice Center under Contract No. 290-02-00009.) Agency for Healthcare Research and Quality, Rockville, MD. Feb 2008
45. Wilt TJ, Brawer MK, Barry MJ, Jones KM, Kwon Y, Gingrich JR, Aronson WJ, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Fox S (2009) The prostate cancer intervention versus observation trial: VA/NCI/AHRQ cooperative studies program 407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials 30: 81-87
46. Wilt TJ, Brawer MB, Jones KM et al (2012) The prostate cancer intervention versus observation trial. N Engl J Med 367: 203-213